ANI PHARMACEUTICALS INC·4

Jul 17, 7:07 PM ET

Shanmugam Muthusamy 4

4 · ANI PHARMACEUTICALS INC · Filed Jul 17, 2024

Insider Transaction Report

Form 4
Period: 2024-07-15
Shanmugam Muthusamy
DirectorHEAD OF R&D, COO-NOVITIUM OPS
Transactions
  • Sale

    Common Stock

    2024-07-16$64.27/sh22,000$1,413,940649,620 total(indirect: By LLC)
  • Sale

    Common Stock

    2024-07-15$63.38/sh11,000$697,180671,620 total(indirect: By LLC)
  • Sale

    Common Stock

    2024-07-17$63.16/sh14,257$900,472635,363 total(indirect: By LLC)
Holdings
  • Common Stock

    68,652
  • Common Stock

    (indirect: By LLC)
    5,000
Footnotes (6)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023.
  • [F2]The shares were sold in multiple trades at prices ranging from $62.47 to $64.19. The price reported above reflects the weighted average sales price.
  • [F3]The reporting person holds voting and dispositive power over the shares held by Esjay LLC.
  • [F4]The shares were sold in multiple trades at prices ranging from $63.25 to $64.91. The price reported above reflects the weighted average sales price.
  • [F5]The shares were sold in multiple trades at prices ranging from $62.62 to $64.21. The price reported above reflects the weighted average sales price.
  • [F6]The Reporting Person holds voting and dispositive power over the shares held by SS Pharma LLC.

Documents

1 file
  • 4
    wk-form4_1721257659.xmlPrimary

    FORM 4